Atara Biotherapeutics, Inc. (NASDAQ:ATRA) SVP Sells $16,217.88 in Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRAGet Rating) SVP Amar Murugan sold 3,612 shares of the business’s stock in a transaction on Wednesday, November 16th. The shares were sold at an average price of $4.49, for a total transaction of $16,217.88. Following the completion of the transaction, the senior vice president now directly owns 127,586 shares of the company’s stock, valued at approximately $572,861.14. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Atara Biotherapeutics Price Performance

ATRA stock opened at $4.27 on Monday. The stock has a market capitalization of $405.13 million, a P/E ratio of -1.73 and a beta of 1.02. Atara Biotherapeutics, Inc. has a fifty-two week low of $2.83 and a fifty-two week high of $18.85. The business has a 50-day moving average of $4.24 and a 200-day moving average of $4.86.

Hedge Funds Weigh In On Atara Biotherapeutics

A number of large investors have recently bought and sold shares of the company. Balyasny Asset Management LLC raised its holdings in shares of Atara Biotherapeutics by 213.3% in the third quarter. Balyasny Asset Management LLC now owns 58,472 shares of the biotechnology company’s stock valued at $221,000 after purchasing an additional 39,806 shares during the last quarter. BNP Paribas Arbitrage SNC boosted its holdings in Atara Biotherapeutics by 637.5% during the third quarter. BNP Paribas Arbitrage SNC now owns 198,267 shares of the biotechnology company’s stock worth $749,000 after purchasing an additional 171,382 shares during the last quarter. Alliancebernstein L.P. grew its position in Atara Biotherapeutics by 43.4% in the third quarter. Alliancebernstein L.P. now owns 107,040 shares of the biotechnology company’s stock valued at $405,000 after purchasing an additional 32,400 shares in the last quarter. State Street Corp increased its stake in Atara Biotherapeutics by 30.1% in the 3rd quarter. State Street Corp now owns 8,097,353 shares of the biotechnology company’s stock valued at $30,608,000 after buying an additional 1,875,667 shares during the last quarter. Finally, Public Employees Retirement System of Ohio lifted its position in Atara Biotherapeutics by 83.3% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 255,611 shares of the biotechnology company’s stock worth $966,000 after buying an additional 116,134 shares in the last quarter.

Analysts Set New Price Targets

A number of research firms have issued reports on ATRA. Mizuho decreased their target price on Atara Biotherapeutics from $39.00 to $31.00 and set a “buy” rating for the company in a research note on Tuesday, August 16th. StockNews.com assumed coverage on Atara Biotherapeutics in a research report on Wednesday, October 12th. They issued a “hold” rating for the company. Finally, The Goldman Sachs Group dropped their target price on shares of Atara Biotherapeutics from $4.00 to $3.00 and set a “sell” rating on the stock in a report on Tuesday, August 9th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Atara Biotherapeutics presently has an average rating of “Hold” and a consensus price target of $18.71.

Atara Biotherapeutics Company Profile

(Get Rating)

Atara Biotherapeutics, Inc is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need.

Recommended Stories

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.